Immunotherapy in the context of hematopoietic stem cell transplantation: The emerging role of natural killer cells and mesenchymal stromal cells

Pediatric Clinics of North America

Volumn 57, Issue 1, 2010, Pages 97-121

  Lankester, Arjan C ^a   Ball, Lynne M ^a   Lang, Peter ^b   Handgretinger, Rupert ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Hematopoietic stem cell transplantation; Immunotherapy; Mesenchymal stromal cells; Natural killer cells

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; INTERLEUKIN 2; STEROID;

ALLERGIC ENCEPHALOMYELITIS; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DENDRITIC CELL; DRUG MEGADOSE; ENGRAFTMENT; EWING SARCOMA; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; LEUKEMIA; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NEUROBLASTOMA; NONHUMAN; OSTEOGENESIS IMPERFECTA; PATIENT SAFETY; REVIEW; RHABDOMYOSARCOMA; SOLID TUMOR; STEM CELL EXPANSION; STEM CELL MOBILIZATION; T LYMPHOCYTE; THERAPY EFFECT; TUMOR IMMUNITY; VIRUS IMMUNITY;

ANIMALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MESENCHYMAL STEM CELLS; MESODERM; NEOPLASMS; STROMAL CELLS;

EID: 77951073138     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2009.12.001     Document Type: Review

References (146)

1. Kiessling R., Klein E., Pross H., et al. " Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 1975, 5:117-121.
2. Lanier L.L., Phillips J.H., Hackett J., et al. Natural killer cells: definition of a cell type rather than a function. J Immunother 1986, 137:2735-2739.
3. Caligiuri M.A. Human natural killer cells. Blood 2008, 112:461-469.
4. Ljunggren H.G., Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Environ Monit 1985, 162:1745-1759.
5. Ljunggren H.G., Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990, 11:237-244.
6. Boyton R.J., Altmann D.M. Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin Exp Immunol 2007, 149:1-8.
7. Moretta L., Bottino C., Pende D., et al. Different checkpoints in human NK-cell activation. Trends Immunol 2004, 25:670-676.
8. Bottino C., Moretta L., Pende D., et al. Learning how to discriminate between friends and enemies, a lesson from Natural Killer cells. Mol Immunol 2004, 41:569-575.
9. Braud V.M., Allan D.S., O'Callaghan C.A., et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998, 391:795-799.
10. Kaiser B.K., Barahmand-Pour F., Paulsene W., et al. Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. J Immunother 2005, 174:2878-2884.
11. Moretta A., Bottino C., Vitale M., et al. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 1996, 14:619-648.
12. Yokoyama W.M., Plougastel B.F. Immune functions encoded by the natural killer gene complex. Nat Rev Immunol 2003, 3:304-316.
13. Uhrberg M., Valiante N.M., Shum B.P., et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997, 7:753-763.
14. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989, 47:187-376.
15. Pende D., Rivera P., Marcenaro S., et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002, 62:6178-6186.
16. Cerwenka A., Lanier L.L. NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 2003, 61:335-343.
17. Pende D., Bottino C., Castriconi R., et al. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol Immunol 2005, 42:463-469.
18. Sivori S., Carlomagno S., Moretta L., et al. Comparison of different CpG oligodeoxynucleotide classes for their capability to stimulate human NK cells. Eur J Immunol 2006, 36:961-967.
19. Zamai L., Ponti C., Mirandola P., et al. NK cells and cancer. J Immunother 2007, 178:4011-4016.
20. Imai K., Matsuyama S., Miyake S., et al. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000, 356:1795-1799.
21. Cudkowicz G., Bennett M. Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice. J Environ Monit 1971, 134:1513-1528.
22. Lowdell M.W., Ray N., Craston R., et al. The in vitro detection of anti-leukaemia-specific cytotoxicity after autologous bone marrow transplantation for acute leukaemia. Bone Marrow Transplant 1997, 19:891-897.
23. Lowdell M.W., Craston R., Samuel D., et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol 2002, 117:821-827.
24. Tajima F., Kawatani T., Endo A., et al. Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. Leukemia 1996, 10:478-482.
25. Siegler U., Kalberer C.P., Nowbakht P., et al. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice. Leukemia 2005, 19:2215-2222.
26. Salih H.R., Antropius H., Gieseke F., et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003, 102:1389-1396.
27. Afify Z.A., bdel-Mageed A., Findley H.W., et al. Cytotoxicity of purified Leu 19+ cells from the peripheral blood of children with acute lymphocytic leukemia. Cancer 1990, 66:469-473.
28. Mageed A.A., Findley H.W., Franco C., et al. Natural killer cells in children with acute leukemia. The effect of interleukin-2. Cancer 1987, 60:2913-2918.
29. Findley H.W., Abdel M.A., Nasr S.A., et al. Recombinant interleukin-2 activates peripheral blood lymphocytes from children with acute leukemia to kill autologous leukemic cells. Cancer 1988, 62:1928-1931.
30. Coca S., Perez-Piqueras J., Martinez D., et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997, 79:2320-2328.
31. Ishigami S., Natsugoe S., Tokuda K., et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000, 88:577-583.
32. Alvarado C.S., Findley H.W., Chan W.C., et al. Natural killer cells in children with malignant solid tumors. Effect of recombinant interferon-alpha and interleukin-2 on natural killer cell function against tumor cell lines. Cancer 1989, 63:83-89.
33. Velardi A. Role of KIRs and KIR ligands in hematopoietic transplantation. Curr Opin Immunol 2008, 20:581-587.
34. Velardi A., Ruggeri L., Mancusi A., et al. Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. Curr Opin Immunol 2009, 21:525-530.
35. Pfeiffer M., Schumm M., Feuchtinger T., et al. Intensity of HLA class I expression and KIR-mismatch determine NK-cell mediated lysis of leukaemic blasts from children with acute lymphatic leukaemia. Br J Haematol 2007, 138:97-100.
36. Prigione I., Corrias M.V., Airoldi I., et al. Immunogenicity of human neuroblastoma. Ann N Y Acad Sci 2004, 1028:69-80.
37. Handgretinger R., Lang P., Schumm M., et al. Immunological aspects of haploidentical stem cell transplantation in children. Ann N Y Acad Sci 2001, 938:340-357. [discussion: 357-8].
38. Feuchtinger T., Pfeiffer M., Pfaffle A., et al. Cytolytic activity of NK cell clones against acute childhood precursor-B-cell leukaemia is influenced by HLA class I expression on blasts and the differential KIR phenotype of NK clones. Bone Marrow Transplant 2009, 43:875-881.
39. Ruggeri L., Capanni M., Casucci M., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999, 94:333-339.
40. Ruggeri L., Mancusi A., Capanni M., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007, 110:433-440.
41. Leung W., Iyengar R., Turner V., et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunother 2004, 172:644-650.
42. Chen X., Knowles J., Barfield R.C., et al. A novel approach for quantification of KIR expression in healthy donors and pediatric recipients of hematopoietic SCTs. Bone Marrow Transplant 2009, 43:525-532.
43. Leung W., Iyengar R., Triplett B., et al. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunother 2005, 174:6540-6545.
44. Hsu K.C., Keever-Taylor C.A., Wilton A., et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005, 105:4878-4884.
45. Miller J.S., Cooley S., Parham P., et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007, 109:5058-5061.
46. Farag S.S., Bacigalupo A., Eapen M., et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 2006, 12:876-884.
47. Willemze R., Rodrigues C.A., Labopin M., et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009, 23:492-500.
48. Verheyden S., Demanet C. NK cell receptors and their ligands in leukemia. Leukemia 2008, 22:249-257.
49. Lowe E.J., Turner V., Handgretinger R., et al. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. Br J Haematol 2003, 123:323-326.
50. Langenkamp U., Siegler U., Jorger S., et al. Human acute myeloid leukemia CD34+CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells. Haematologica 2009, 94:1590-1594.
51. Savani B.N., Rezvani K., Mielke S., et al. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2006, 107:1688-1695.
52. Fischer J.C., Ottinger H., Ferencik S., et al. Relevance of C1 and C2 epitopes for hemopoietic stem cell transplantation: role for sequential acquisition of HLA-C-specific inhibitory killer Ig-like receptor. J Immunother 2007, 178:3918-3923.
53. Teltschik F., Lang P., Pfeiffer H., et al. Long-term IL2 therapy after transplantation of T-cell depleted stem cells from alternative donors in children [abstract]. Bone Marrow Transplant 2007, 39(Suppl 1):S185.
54. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
55. Handgretinger R., Chen X., Pfeiffer M., et al. Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation. Ann N Y Acad Sci 2007, 1106:279-289.
56. Bethge W.A., Faul C., Bornhauser M., et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Blood Cells Mol Dis 2008, 40:13-19.
57. Barfield R.C., Otto M., Houston J., et al. A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation. Cytotherapy 2004, 6:1-6.
58. Rodella L., Zamai L., Rezzani R., et al. Interleukin 2 and interleukin 15 differentially predispose natural killer cells to apoptosis mediated by endothelial and tumour cells. Br J Haematol 2001, 115:442-450.
59. Pfeiffer M., Lang P., Schumm M., et al. IL-15 activated CD3/10 depleted grafts for haploidentical transplantation in children: strongly increased NK activity in vitro and excellent tolerability in vivo [abstract]. Bone Marrow Transplant 2008, 41. S51.
60. Lang P., Barbin K., Feuchtinger T., et al. Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts. Blood 2004, 103:3982-3985.
61. Pfeiffer M., Stanojevic S., Feuchtinger T., et al. Rituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantation. Bone Marrow Transplant 2005, 36:91-97.
62. Triplett B., Handgretinger R., Pui C.H., et al. KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia. Blood 2006, 107:1238-1239.
63. Imai C., Iwamoto S., Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005, 106:376-383.
64. Fujisaki H., Kakuda H., Shimasaki N., et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009, 69:4010-4017.
65. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
66. Perez-Martinez A., Leung W., Munoz E., et al. KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. Pediatr Blood Cancer 2009, 53:120-124.
67. Re F., Staudacher C., Zamai L., et al. Killer cell Ig-like receptors ligand-mismatched, alloreactive natural killer cells lyse primary solid tumors. Cancer 2006, 107:640-648.
68. Igarashi T., Wynberg J., Srinivasan R., et al. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 2004, 104:170-177.
69. Verhoeven D.H., de Hooge A.S., Mooiman E.C., et al. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol 2008, 45:3917-3925.
70. Lang P., Pfeiffer M., Muller I., et al. Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects. Klin Padiatr 2006, 218:321-326.
71. Fibbe W.E., Lazarus H.M. Mesenchymal stem cells and hematopoietic stem cell transplantation. Clinical bone marrow and blood stem cell transplantation 2004, 67-78. Cambridge University Press, Cambridge. 3rd edition. K. Atkinson, R. Champlin, M.A. Brenner (Eds.).
72. Friedenstein A.J., Deriglasova U.F., Kulagina N.N., et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974, 2:83-92.
73. Owen M. Marrow stromal stem cells. J Cell Sci Suppl 1988, 10:63-76.
74. Prockop D.J. Marrow stromal cells as stem cells for non-hematopoietic tissues. Science 1997, 276:71-74.
75. Majumdar M.K., Thiede M.A., Mosca J.D., et al. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. J Cell Physiol 1998, 176:57-66.
76. Almeida-Porada G., Flake A.W., Glimp H.A., et al. Cotransplantation of stroma results in enhancement of engraftment and early expression of donor hematopoietic stem cells in utero. Exp Hematol 1999, 27:1569-1575.
77. In't Anker P.S., Noort W.A., Kruisselbrink A.B., et al. Non expanded primary lung and bone marrow-derived mesenchymal cells promote the engraftment of umbilical cord blood-derived CD34 (+) cells in NOD/SCID mice. Exp Hematol 2003, 31:881-889.
78. Horwitz E.M., Le Blanc K., Dominici M., et al. Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy 2005, 7:393-395.
79. Nathanson M.A. Bone matrix-directed chondrogenesis of muscle in vitro. Clin Orthop 1985, 200:142-158.
80. Nakahara H., Dennis J.E., Bruder S.P., et al. In vitro differentiation of bone and hypertrophic cartilage from periosteal-derived cells. Exp Cell Res 1991, 195:492-503.
81. Campagnoli C., Roberts I.A., Kumar S., et al. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001, 98:2396-2402.
82. Fernandez M., Simon V., Herrera G., et al. Detection of stromal cells in peripheral blood progenitor cell collections from breast cancer patients. Bone Marrow Transplant 1997, 20:265-271.
83. Lazarus H.M., Haynesworth S.E., Gerson S.L., et al. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995, 16:557-564.
84. Erices A., Conget P., Minguell J.J. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000, 109:235-242.
85. Bieback K., Kluter H. Mesenchymal stromal cells from umbilical cord blood. Curr Stem Cell Res Ther 2007, 2:310-323.
86. In't Anker P.S., Scherjon S.A., Kleijburg-Van Der Keur C., et al. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood 2003, 102:1548-1549.
87. Bernardo M.E., Emons J.A., Karperien M., et al. Human mesenchymal stem cells derived from bone marrow display a better chondrogenic differentiation compared with other sources. Connect Tissue Res 2007, 48:132-140.
88. Bernardo M.E., Avanzini M.A., Perotti C., et al. Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. J Cell Physiol 2007, 211:121-130.
89. Avanzini M.A., Bernardo M.E., Cometa A.M., et al. Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypical and functional comparison between umbilical cord blood- and bone marrow-derived progenitors. Hematologica 2009, 94:1649-1660.
90. Vogel J.P., Szalay K., Geiger F., et al. Platelet-rich plasma improves expansion of human mesenchymal stem cells and retains differentiation capacity and in vivo bone formation in calcium phosphate ceramics. Platelets 2006, 17:462-469.
91. Doucet C., Ernou I., Zhang Y., et al. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 2005, 205:228-236.
92. Schallmoser K., Bartmann C., Rohde E., et al. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion 2007, 47:1436-1446.
93. Tolar J., Nauta A.J., Osborn M.J., et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007, 25:371-379.
94. Bernardo M.E., Zaffaroni N., Novara F., et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 2007, 67:9142-9149.
95. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008, 8:726-736.
96. Di Nicola M., Carlo-Stella C., Magni M., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
97. Krampera M., Glennie S., Dyson J., et al. Bone marrow mesenchymal stem cells inhibit the response of naïve and memory antigen-specific T-cells to their cognate peptide. Blood 2004, 101:3722-3729.
98. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
99. Sotiropoulou P.A., Perz S.A., Gritzapis A.D., et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006, 24:74-85.
100. Nauta A.J., Westerhuis G., Kruisselbrink A.B., et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006, 108:2114-2120.
101. Meisel R., Ziber A., Laryea M., et al. Human bone marrow stromal cells inhibit allogeneic responses by indoleamine 2,3 dioxygenase mediated tryptophan degradation. Blood 2004, 103:4619-4621.
102. Glennie S., Soeiro I., Dyson P.J., et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005, 105:2821-2827.
103. Benvenuto F., Ferrari S., Gerdoni E., et al. Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells 2007, 25:1753-1760.
104. Rasmusson I., Ringden O., Sundberg B., et al. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005, 305:33-41.
105. Rasmusson I., Ringden O., Sundberg B., et al. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003, 76:1208-1213.
106. Morandi F., Raffaghello L., Bianchi G., et al. Immunogenicity of human mesenchymal stem cells in HLA-class-I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells 2008, 26:1275-1287.
107. Augello A., Tasso R., Negrini S.M., et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005, 35:1482-1486.
108. Corcione A., Benvenuto F., Ferretti E., et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006, 107:367-372.
109. Traggiai E., Volpi S., Schena F., et al. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 2008, 26:562-569.
110. Rasmusson I., Le Blanc K., Sundberg B., et al. Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol 2007, 65:336-343.
111. Jiang X.X., Zhang Y., Liu B., et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte derived dendritic cells. Blood 2005, 105:4120-4126.
112. Nauta A.J., Kruisselbrink A.B., Lurvink E., et al. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 2006, 177:2080-2087.
113. Li Y.P., Paczesny S., Lauret E., et al. Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J Immunol 2008, 180:1598-1608.
114. Stagg J., Pommey S., Eliopoulos N., et al. Interferon-γ-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood 2006, 107:2570-2577.
115. Spaggiari G.M., Capobianco A., Becchetti S., et al. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006, 107:1484-1490.
116. Almeida-Porada G., Porada C.D., Tran N., et al. Co-transplantation of human stromal cell progenitors into pre-immune fetal sheep results in early appearance of human donor cells in circulation and boosts cell levels in bone marrow at later time points after transplantation. Blood 2000, 95:3620-3627.
117. Krampera M., Cosmi L., Angeli R., et al. Role for interferon-γ in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006, 24:386-398.
118. Ryan J.M., Barry F., Murphy J.M., et al. Interferon-γ does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007, 149:353-363.
119. Ren G., Zhang L., Zhao X., et al. Mesenchymal stem-cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008, 2:141-150.
120. Kogler G., Kögler G., Radke T.F., et al. Cytokine production and hematopoiesis supporting activity of cord blood derived unrestricted somatic stem cells. Exp Hematol 2005, 33:573-583.
121. Selmani Z., Naji A., Zidi I., et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008, 26:212-222.
122. Bartholomew A., Sturgeon C., Siatskas M., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002, 30:42-48.
123. Yanez R., Lamana M.L., Garcia-Castro J., et al. Adipose tissue-derived mesenchymal stem cells (AD-MSC) have in vivo immunosuppressive properties applicable for the control of graft-versus-host disease (GVHD). Stem Cells 2006, 24:2582-2591.
124. Zhang J., Li Y., Chen J., et al. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol 2005, 195:16-26.
125. Djouad F., Fritz V., Apparailly F., et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 2005, 52:1595-1603.
126. Devine S.M., Bartholomew A.M., Mahmud N., et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 2001, 29:244-255.
127. Noort W.A., Kruisselbrink A.B., In't Anker P.S., et al. Mesenchymol stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol 2002, 30:870-878.
128. Ringden O., Uzunel M., Rasmusson I., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
129. Devine S.M., Cobbs C., Jennings M., et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into non-human primates. Blood 2003, 101:2999-3001.
130. Ruster B., Göttig S., Ludwig R.J., et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006, 108:3938-3944.
131. Sordi V., Malosio M.L., Marchesi F., et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005, 106:419-427.
132. Son B.R., Marquez-Curtis L.A., Kucia M., et al. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-Met axes and involves matrix metalloproteinases. Stem Cells 2006, 24:1254-1264.
133. Karp J.M., Teo G.S.L. Mesenchymal stem cell homing: the devil is in the details. Review Cell Stem Cell 2009, 4:206-316.
134. Koc O.N., Gerson S.L., Cooper B.W., et al. Rapid hematopoietic recovery after co-infusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000, 18:307-316.
135. Lazarus H.M., Curtin P., Devine S., et al. Co-transplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005, 11:389-398.
136. Müller I., Kustermann-Kuhn B., Holzwarth C., et al. In vitro analysis of multipotent mesenchymal stromal cells as potential cellular therapeutics in neurometabolic diseases in pediatric patients. Exp Hematol 2006, 34:1413-1419.
137. Koc O.N., Peters C., Aubourg P., et al. Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. Exp Hematol 1999, 27:1675-1681.
138. Krivit W., Shapiro E.G., Lockman L.A., et al. Bone marrow transplantation: treatment for globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy and Hurler syndrome. Handbook of clinical neurology 1996, 87-106. Elsevier Science, Amsterdam. H.W. Moser, P.J. Vinken, G.W. Bruyn (Eds.).
139. Koc O.N., Day J., Nieder M., et al. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002, 30:215-222.
140. Sillence D.O., Rimoin D.L., Danks D.M. Clinical variability in osteogenesis imperfecta-variable expressivity or genetic heterogeneity. Birth Defects Orig Artic Ser 1979, 15:113-129.
141. Horwitz E.M., Prockop D.J., Gordon P.L., et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001, 97:1227-1231.
142. Horwitz E.M., Gordon P.L., Koo W.K., et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002, 99:8932-8937.
143. Ball L.M., Bernardo M.E., Roelofs H., et al. Co-transplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haplo-identical hematopoietic stem cell transplantation. Blood 2007, 110:2765-2767.
144. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
145. Le Blanc K., Frassoni F., Ball L.M., et al. Use of bone marrow derived expanded mesenchymal stem cells in the treatment of steroid refractory acute GvHD. Lancet 2008, 371:1579-1586.
146. Available at:. http://investor.osiris.com/releases.cfm.